The global human growth hormone treatment and drugs market exhibits a valuation of USD 3.55 Billion by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 3.7%, and is expected to hold a market value of around USD 5.26 Billion in 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 3.55 Billion |
| Market Value 2023 | USD 3.67 Billion |
| Market Value 2033 | USD 5.26 Billion |
| CAGR 2023 to 2033 | 3.7% |
| Market Share of Top 5 Countries (2022) | 48.7% |
| Key Market Players | Ankebio Co. Ltd.; Eli Lilly and Company; Emd Serono; Ferring Pharmaceuticals; Genentech Inc.; Gene Science Pharmaceutical Co. Ltd.; Ipsen; LG Life Sciences; Merck KGaA; Novo Nordisk; Ascendis Pharma; Pfizer Inc. |
Human growth hormone (hGH) also known as Somatotropin is a peptide hormone that is crucial for human development and is responsible for cell regeneration, cell reproduction, and growth stimulation. Growth hormone deficit results from the pituitary gland's inability to synthesise growth hormone (GH). Several inherited conditions, including Prader-Willi syndrome, Turner syndrome, and idiopathic short stature (ISS), which causes delayed puberty and shorter-than-average height, can also cause growth hormone insufficiency in humans.
Currently, hGH is frequently misused by bodybuilders, sportsmen, and older adults as an anti-aging medication and as a performance-enhancing anabolic substance. Growth hormone has not received USFDA approval for anti-aging or performance-enhancing uses because it is a prohibited substance.
Medication growth hormones are the suitable short-term treatments for such conditions, which are becoming more and more common among young people and elderly people alike worldwide. Medication for human growth hormone is readily available on the market today, raising awareness of its health benefits and helping manufacturing companies increase their revenue.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Human growth hormone treatment and drugs market expanded at a CAGR of 2.7% for 2017 to 2022 period due to growing incidences of growth hormone insufficiency, urban lifestyle and unhealthy food habits.
The market value for human growth hormone treatment and drugs was around 16.47% of the overall USD 21.25 Billion of the global hormone replacement therapy market in 2022.
Due to increased research and development, increased healthcare expenditure, and improved healthcare infrastructure, the pharmaceutical and healthcare industries are rapidly expanding. Around the world, many hospitals, ambulatory surgical care centers, and clinics are installing cutting-edge devices and equipment.
Rising chronic disease prevalence, rapid advancements in the healthcare and medical sectors, widespread adoption of new tools and techniques, and increased funding from various public and private sectors are further, driving revenue growth in the global hormone replacement therapy market.
The advancement in human biomedical sciences and the discovery of new methods for synthesising long-acting second-generation products like growth hormones or somatotropin has brought down the human hormone growth injection price. This overall drop-in price has further boosted the growth of the human growth hormone treatment and drugs market globally.
Healthcare has undergone a digital revolution in the last decade. Rapid advancements in connected health, mobile technology, artificial intelligence (AI), and gamification, including virtual and augmented reality (VR/AR), are changing how patients are diagnosed, treated, and managed. Typically, digital health solutions are disease-specific and address specific conditions and patient populations.
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 2.50% |
| Jul-Dec (H2), 2021 (A) | 3.19% |
| Jan-Jun (H1),2022 Projected (P) | 2.40% |
| Jan-Jun (H1),2022 Outlook (O) | 2.64% |
| Jul-Dec (H2), 2022 Outlook (O) | 3.49% |
| Jul-Dec (H2), 2022 Projected (P) | 3.17% |
| Jan-Jun (H1), 2023 Projected (P) | 2.90% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 25 ↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 14 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 32 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (A) | 30 ↑ |
Principal Consultant
Urban lifestyles and deteriorating dietary habits leading to significant hormonal imbalance are expected to increase demand for human growth hormone drugs and a wide range of treatment options. Medication growth hormones assist in such situations and are thus, gaining popularity among both young and old people worldwide.
The market is further expected to grow due to a strenuous product pipeline and extensive research and development activities for the development of novel growth hormone therapies.
The market is also expected to be fuelled by a variety of public and private campaigns aimed at raising awareness of growth hormone deficiency and treatment options. The International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a non - profit organisation based in the United States, observes International Children's Growth Awareness Day each year to promote public understanding of the identification and management of growth hormone disorders and to aid in the rapid recovery of people, particularly children.
The use of growth hormone medication has been well established thanks to the efforts of healthcare sectors in every region. However, awareness to use of human growth hormones to treat many deficiency diseases among adults remains low, particularly in developing countries. This fact may significantly impede market participants from reaching their full potential.
In the market for treating growth hormone problems, complications are highly likely. Complications after the treatment include possible growth hormone therapy side effects, such as knee, hip, or other joint soreness; allergic reactions, such as hives, rash, or swelling; and an increase in blood sugar levels. As a result, it prevents the growth of the market.
The high cost of these medications restricts market expansion. Drugs for growth hormone disorders are expensive and may become costly for lower socioeconomic groups.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | The USA |
|---|---|
| Market Share (2023) | 25.9% |
| Market Share (2033) | 24.9% |
| BPS Analysis | -106 |
| Country | China |
|---|---|
| Market Share (2023) | 6.6% |
| Market Share (2033) | 6.8% |
| BPS Analysis | 19 |
| Country | Japan |
|---|---|
| Market Share (2023) | 5.9% |
| Market Share (2033) | 6.3% |
| BPS Analysis | 36 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.0% |
| Market Share (2033) | 4.6% |
| BPS Analysis | -38 |
| Country | Canada |
|---|---|
| Market Share (2023) | 4.9% |
| Market Share (2033) | 5.0% |
| BPS Analysis | 8 |
The USA is set to dominate the global human growth hormone treatment and drugs industry in 2023 with a market share of 25.9%.
The USA has a dominant position in the global market due to the presence of key players, primarily in the USA, who have expertise in manufacturing cutting-edge recombinant human growth hormone injections for the world's growing geriatric population.
According to the American Academy of Paediatrics, one in every 10,000 children in the USA suffers from growth hormone deficiency. Significant chronic and genetics conditions like Prader-Willi syndrome and Turner syndrome are rising. Thus, the increasing sale of growth hormone injections for the treatment of various growth disorders.
Germany is set to hold the largest sector share in Europe. Globally, Germany will hold around 5.0% revenue share in 2023.
The market for HGH medications in Germany is expected to grow due to a better understanding of growth hormonal diseases, a well-established health care infrastructure, and increased research and development, favorable reimbursement policies, and the region's established healthcare ecosystem.
According to the published article in the Deutsches Arzteblatt in 2011, Germany has developed a CrescNet System from last ten years in the Leipzig Treatment Center for early detection and awareness of growth hormone deficiency. Currently CrescNet System includes more than 323 medical practices and more than 22 pediatric endocrinology treatment centers with large number of doctors.
The China market will hold about 6.6% of the global market share in 2023.
The higher population count in China together with advanced research carried out in Chinese biotech companies are anticipated to boost the global market for Injectable human growth hormones at a higher growth rate.
According to a Biapharm in 2022 report, China has a large market for growth hormone products, which are required by around 7 million Chinese children for the treatment of short stature. HGH treatment for children is in high demand in China today, even when there is no medical abnormality. This has allowed domestic HGH manufacturers to expand while also attracting global pharmaceutical giants to the lucrative market.
Oral route of administration for leads the global market. In 2023, this segment is expected to hold about 43.3% within the global market.
Growth hormone deficiency in children is commonly perceived as a short height condition in boys and girls. Therefore, the human growth hormone pills for height are a popular oral product with huge growth potential during the forecast period.
The USA FDA (Food and Drug Administration) approved Macrilen (macimorelin) for oral administration in December 2017. This GH secretagogue receptor agonist is used to treat adult growth hormone deficiency (AGHD). Oral macimorelin administration is a simple, well tolerated, reproducible, and safe diagnostic test for AGHD, with the only reported side effect being bad taste.
Growth hormone deficiency (GHD) will lead the global market with the value share of about 27.7% in 2023.
As a broad category, growth hormone (GH) deficiency disease creates the most significant demand for human growth hormone shots in the healthcare sector. With the growing awareness among general population about the availability of treatment facilities and the discovery of new drugs, this segment is expected to hold the leading position for some more years ahead. Furthermore, GH deficiency in children is the major driving factor for this segment's human growth hormone treatment and drugs market.
Hospital pharmacies segment will hold the market share of 55.3% in 2023 globally.
Hormonal deficiency is a very serious concern for children and adults involves very complicated management of human growth hormone replacement therapy that skilled healthcare professionals in hospital setups must carry out. Attributing to this reason, the hospital pharmacy is the largest revenue generator for the global market accounting for more than about 50% of the stock volume of hGH human growth hormone injections for sale in the market.
Innovations in the field of designing new chemical formulations with greater efficiency is expected to increase the popularity of human growth hormone injections for adults in the market benefitting the market players. Key players within this space actively approaching mergers and acquisitions to expand their market reach and increase the volume of human growth hormone injections.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the human growth hormone treatment and drugs market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC countries, Türkiye, South Africa and North Africa. |
| Key Market Segments Covered | Route of Administration, Application, Distribution Channel, and Region |
| Key Companies Profiled | Ankebio Co. Ltd.; Eli Lilly and Company; Emd Serono; Ferring Pharmaceuticals; Genentech Inc.; Gene Science Pharmaceutical Co. Ltd.; Ipsen, LG Life Sciences; Merck KGaA; Novo Nordisk; Ascendis Pharma; Pfizer Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is expected to be valued at USD 3.55 billion in 2023.
Until 2033, the market may rise at a 3.7% CAGR.
By 2033, the market may total around USD 5.26 billion.
Sedentary lifestyle drives market expansion.
North America is expected to dominate the market until 2033.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Subcutaneous 7.2. Intramuscular 7.3. Intravenous 7.4. Oral 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 8.1. Growth Hormone Deficiency 8.2. Turner Syndrome 8.3. Idiopathic Short Stature (ISS) 8.4. Prader-Willi Syndrome (PWS) 8.5. Other Applications 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 9.1. Hospital Pharmacy 9.2. Specialty Pharmacy 9.3. Retail Pharmacy 9.4. Online Pharmacy 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. East Asia 10.5. South Asia 10.6. Oceania 10.7. The Middle East and Africa 11. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 17. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Market Structure Analysis 19. Competition Analysis 19.1. Ankebio Co. Ltd. 19.2. Eli Lilly and Company 19.3. Emd Serono 19.4. Feeing Pharmaceuticals 19.5. Genentech Inc. 19.6. Gene Science Pharmaceutical Co. Ltd. 19.7. Ipsen 19.8. LG Life Sciences 19.9. Merck KGaA 19.10. Novo Nordisk 19.11. Ascendis Pharma 19.12. Pfizer Inc. 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Human Growth Hormone Treatment and Drugs Market
